NCT05354466View on ClinicalTrials.gov

Perioperative Respiratory Adverse events_sugammadex

PHASE4CompletedINTERVENTIONAL
Enrollment

174

Participants

Timeline

Start Date

June 27, 2022

Primary Completion Date

September 4, 2024

Study Completion Date

September 4, 2024

Conditions
Respiratory Complication
Interventions
DRUG

Sugammadex injection

sugammadex as reversal agent

DRUG

Neostigmine

neostigmine as a reversal agent

Trial Locations (1)

Unknown

Seoul national university hospital, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER